Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Phase 1/2 Unknown
72 enrolled
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Phase 2 Unknown
480 enrolled
B2023-153
Phase 2 Unknown
48 enrolled
ROME
Phase 2 Unknown
400 enrolled
BiOnHER
Unknown
80 enrolled
HIST-RIC
Phase 2 Unknown
101 enrolled
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
Phase 2 Unknown
67 enrolled
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Phase 2 Unknown
30 enrolled
VinCaT
Phase 2 Unknown
39 enrolled
easy laugh
Phase NA Unknown
204 enrolled
NeoPATH
Phase 2 Unknown
100 enrolled
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Phase 2 Unknown
52 enrolled
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Phase 2 Unknown
126 enrolled
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
Phase 2 Unknown
216 enrolled
HERES
Phase 2 Unknown
24 enrolled
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Phase 2 Unknown
100 enrolled
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
Phase 2 Unknown
209 enrolled
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Phase 3 Unknown
120 enrolled
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Phase 1/2 Unknown
95 enrolled
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Phase 2 Unknown
34 enrolled
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Phase 3 Unknown
240 enrolled
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Phase 2 Unknown
40 enrolled
Efficacy and Safety of Precision Therapy in Refractory Tumor
Phase 2 Unknown
300 enrolled
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Unknown
50 enrolled
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Phase 2 Unknown
77 enrolled
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Phase 2/3 Unknown
190 enrolled
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
Unknown
120 enrolled
HERMET
Phase 2 Unknown
100 enrolled
NeoTPPF
Phase 2 Unknown
37 enrolled
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Phase 2 Unknown
40 enrolled
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Unknown
240 enrolled
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Phase 2 Unknown
60 enrolled
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Unknown
30 enrolled
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
Phase 2 Unknown
60 enrolled
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Phase 2 Unknown
120 enrolled
Pyramid
Phase 2 Unknown
490 enrolled
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Phase 1/2 Unknown
50 enrolled
Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
Phase 2 Unknown
57 enrolled
Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer
Phase 1/2 Unknown
41 enrolled
B-DOCT
Phase 2 Unknown
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Unknown
80 enrolled
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Unknown
200 enrolled
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis
Phase 2 Unknown
100 enrolled
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Phase 2 Unknown
90 enrolled
SOBER
Phase 2 Unknown
112 enrolled
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer
Phase 2 Unknown
200 enrolled
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Phase 1/2 Unknown
40 enrolled
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Phase 2 Unknown
37 enrolled
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
Phase 1/2 Unknown
20 enrolled
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Phase 2 Unknown
77 enrolled